O'Neill S J, Millar E D, Coles S J, Bachand R T
Beaumont Hospital, Dublin.
Ir Med J. 1991 Mar;84(1):33-5.
A total of 2,351 adult patients were recruited into a multi-centre open general practice study to investigate the safety and efficacy of Clarithromycin 250 mg b.d. for seven days in the management of acute mild to moderate respiratory tract infections. Overall a clinical success rate of 93.2% was seen with respect to assessment of the response of the respiratory tract infection to Clarithromycin therapy. Summary statistics are presented for each diagnosis recorded. A total of 110 (4.7%) adverse events were reported. Of these 71 (3%) were related to the gastrointestinal tract e.g. nausea, vomiting etc. The above results demonstrate that Clarithromycin in a dose of 250 mg b.d. is a well tolerated and effective therapy in the management of acute mild to moderate respiratory tract infections.
共有2351名成年患者被纳入一项多中心开放性全科医学研究，以调查250毫克克拉霉素每日两次、连用七天治疗急性轻至中度呼吸道感染的安全性和有效性。总体而言，就呼吸道感染对克拉霉素治疗的反应评估来看，临床成功率为93.2%。针对记录的每种诊断给出了汇总统计数据。共报告了110起（4.7%）不良事件。其中71起（3%）与胃肠道有关，如恶心、呕吐等。上述结果表明，250毫克克拉霉素每日两次的剂量在治疗急性轻至中度呼吸道感染方面是耐受性良好且有效的疗法。
